News Release

DNA in blood can track cancer development and response in real time

Peer-Reviewed Publication

Cancer Research UK

Scientists have shown for the first time that tumour DNA shed into the bloodstream can be used to track cancers in real time as they evolve and respond to treatment, according to a new Cancer Research UK study published in the journal Nature Communications today (Wednesday).

Over three years, researchers at the University of Cambridge took surgical tumour samples (biopsies) and blood samples from a patient with breast cancer that had already spread to other parts of her body. They carefully studied small fragments of DNA from dying tumour cells that are shed into the blood, comparing them with DNA from the biopsy that was taken at the same point in time.

The results show that the DNA in the blood samples matched up with that from the biopsies, reflecting the same pattern and timing of genetic changes appearing as the cancer developed and responded to treatment. The results provide the first proof-of-principle that analysing tumour DNA in the blood can accurately monitor cancer within the body.

Study author Professor Carlos Caldas, senior group leader at the Cancer Research UK Cambridge Institute, said: "This definitively shows that we can use blood-based DNA tests to track the progress of cancer in real time. The findings could change the way we monitor patients, and may be especially important for people with cancers that are difficult to reach, as taking a biopsy can sometimes be quite an invasive procedure."

The patient in the study had breast cancer that had already spread to a number of other organs. The researchers - part of a collaborative team effort involving the Carlos Caldas and Nitzan Rozenfeld laboratories at the Cancer Research UK Cambridge Institute - were even able to distinguish between the different secondary cancers and examine how each of the tumours was responding to treatment.

Professor Caldas added: "We were able to use the blood tests to map out the disease as it progressed. We now need to see if this works in more patients and other cancer types, but this is an exciting first step."

Dr Kat Arney, science information manager at Cancer Research UK, said: "Spotting tumour DNA in the bloodstream is a really promising area of research, and has the potential to give doctors valuable clues about a patient's disease without having to take repeated tumour samples.

"For now, surgical biopsies still play an important role in diagnosing and monitoring cancers. But this work gives us a window into the future, where we'll use less invasive techniques to track the disease in real time."


For media enquiries please contact Greg Jones on 020 3469 8311 or, out-of-hours, the duty press officer on 07050 264 059

Notes to Editors:

Murtaza, M. et al, 'Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer'. Nature Communications, 2015. DOI: 10.1038/NCOMMS9760

About Cancer Research UK

  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
  • Today, 2 in 4 people survive cancer. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit Follow us on Twitter and Facebook.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.